SAN CARLOS, Calif., June 10, 2025 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conference:Goldman Sachs Global Healthcare ConferenceFireside Chat: June 11, 2025 at 1:20 p.m. ETMiami, FLThe live and archived webcasts will be available at https://ir.iovance.com/news-events/events-presentations. About Iovance Biotherapeutics, Inc.  Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing...

Advances Emissions Goals, Completes Double Materiality Assessment and Highlights Positive Customer Impact LIBERTY LAKE, Wash., June 10, 2025 (GLOBE NEWSWIRE) — Itron, Inc. (NASDAQ: ITRI), which is innovating new ways for utilities and cities to manage energy and water, today released its 2024 Corporate Sustainability Report. The report details Itron’s environmental, social and governance (ESG) strategy and highlights how the company is empowering cities and utilities to boost efficiency, reduce emissions and build climate-resilient communities equipped to tackle a range of challenges including resource scarcity and infrastructure strain. “At Itron, sustainability is a responsibility we embrace every day,” said Tom Deitrich, president and CEO of Itron. “This year, Itron completed our first enterprise-wide double materiality assessment,...

LOWELL, Mass., June 10, 2025 (GLOBE NEWSWIRE) — MACOM Technology Solutions Inc. (“MACOM”), a leading supplier of semiconductor products, today announced availability of a wideband front end module (FEM) covering 2 to 18 GHz. Ideal for electronic countermeasures (ECM) and phased array radar applications, the miniature multi-chip ENGSD00088 Transmit/Receive Module integrates a high power 3-stage Gallium Nitride (GaN) Power Amplifier (PA), a 3-stage Gallium Arsenide (GaAs) Low Noise Amplifier (LNA) and a transmit/receive (T/R) switch with a fail-safe antenna termination, all within a compact package. The transmit path delivers 2.5 W typical saturated output power with power added efficiency (PAE) of 24%, along with 25 dB of large signal gain. The receive side provides 27 dB of gain with a low noise figure of 3.5 dB and 26 dBm output...

Miami, FL, June 10, 2025 (GLOBE NEWSWIRE) — Onar Holding Corporation (OTCQB: ONAR), a leading marketing technology company and network of marketing agencies, today announced the appointment of Howard Palefsky to ONAR’s Board of Directors. Palefsky, an esteemed CEO, VC & PE partner, entrepreneur, board member, chair, and investor with experience across the life sciences, healthcare, and medical technology industries, will also chair the Company’s Governance and Nominating Committee. “It is an honor to welcome Howard to our Board of Directors and as Chair of our Governance and Nominating Committee,” stated Claude Zdanow, CEO of ONAR. “Howard’s extensive expertise with financial markets and public companies, coupled with his experience in healthcare, will be invaluable to our company’s growth and further expansion in the...

Council formed to support VERSES® in driving government, enterprise, and global market adoption of Genius™ VANCOUVER, British Columbia, June 10, 2025 (GLOBE NEWSWIRE) — VERSES AI Inc. (CBOE: VERS) (OTCQB: VRSSF) (“VERSES” or the “Company”), a cognitive computing company specializing in next-generation agentic software systems, today announced the appointment of Dr. David Bray, Ph.D., as Chair of its newly formed Strategic Advisory Council. As Strategic Advisory Chair, Dr. David Bray is expected to assist the Company in assembling a council of experts across industry, policy, and technology, aimed at accelerating the Company’s strategic growth and driving market adoption across both private and public sectors. Dr. Bray is a globally recognized expert on AI, data, and cybersecurity. He was named one of the “Top 24 Americans...

CHENNAI, India, June 10, 2025 (GLOBE NEWSWIRE) — Sify Technologies Ltd. (Nasdaq: Sify) (the “Company”), a leading integrated information communications technology (or ICT) Solutions and Services provider in India, notified the Nasdaq Stock Market (“Nasdaq”) on May 21, 2025 that, consequent to the resignation of Dr. Ajay Kumar from the Company’s Board of Directors (the “Board”), the Company was in non-compliance with Nasdaq Listing Rule 5605(b)(1), requiring that the majority of the Board be composed of independent directors, and Nasdaq Listing Rule 5605(c)(2), requiring that there be at least three members of the Board’s audit committee. Dr. Kumar resigned to take charge of a constitutional responsibility pursuant to the order of the Hon’ble President of India. The Company also indicated its intent to rely on the cure periods...

COLUMBUS, Ohio, June 10, 2025 (GLOBE NEWSWIRE) — Worthington Enterprises Inc. (NYSE: WOR) will hold its quarterly earnings conference call Wednesday, June 25 at 8:30 a.m. ET. The Company will discuss its fiscal fourth quarter results, which will be released after the market closes on June 24. Please click here to register for the June 25 live audio webcast or visit IR.worthingtonenterprises.com. For those unable to listen live, a replay will be available in the Investors section of the Company’s website approximately two hours after the completion of the call and will be archived for one year.LIVE CONFERENCE CALL DETAILSDate: Wednesday, June 25, 2025Webcast Link: https://events.q4inc.com/attendee/393759253Starting Time: 8:30 a.m. ETConference ID: 1777337Domestic Participants: 888-330-3567   About Worthington...

Novo Nordisk to present data from STEP UP trial on a higher dose of Wegovy® (semaglutide 7.2 mg) for those in need of greater weight loss Data will expand semaglutide evidence in both a clinical and real-world setting, including cardiometabolic and kidney health benefits for those with obesity and diabetes Novo Nordisk continues to pioneer obesity innovation, including presentation of full Phase 3 REDEFINE 1 and 2 trial results, providing insights into the transformational potential of CagriSemaBagsværd, Denmark, 10 June – Novo Nordisk today announced that new data from its industry-leading portfolio in metabolic and cardiovascular health will be showcased at the upcoming American Diabetes Association (ADA) 85th Scientific Sessions taking place in Chicago US, 20 – 23 June 2025. A total of 29 abstracts will be presented, including...